A short list, and every item earns its place.
We carry what practices, med spas, and clinics actually run their programs on, compounded by credentialed US pharmacies. We would rather do a focused list properly than publish a catalog nobody can stand behind. Strengths, vial sizes, and shipping vary by pharmacy and by state.
Compounded GLP-1 therapy
The engine of most weight programs. Cold chain shipped and monitored, released against per-lot testing. Semaglutide is supplied as base, never as a salt form, which is a line a lot of the market does not hold.
| Medication | Form | Presentations |
|---|---|---|
| Semaglutide | Injectable, cold chain | Vial sizes vary by pharmacy |
| Tirzepatide | Injectable, cold chain | Concentrations and vial sizes vary by pharmacy |
NAD+ therapy
Drug-grade active ingredient from an FDA-registered supplier, never food grade. Per-lot endotoxin and sterility testing before anything is released. If you have ever wondered what is actually in a NAD+ vial, this is the answer you want.
| Medication | Form | Presentations |
|---|---|---|
| NAD+ | Injectable, cold chain | Multi-dose vial |
The rest of the order
The oral adjuncts and injection supplies a program needs, on the same order and the same invoice, so your team is not placing a second order somewhere else for the boring parts.
| Item | Form | Notes |
|---|---|---|
| Oral adjuncts | Capsule | Non-controlled only |
| Bacteriostatic water | Solution | Ordered alongside an injectable therapy |
What a pharmacy proves before it earns your orders.
This is the part of compounded medicine nobody markets and everybody should ask about. A pharmacy completes the whole package before its first order routes, and refreshes it every year.
- Per-lot certificates of analysis, with endotoxin and sterility release testing on sterile preparations.
- Potency of 90 to 110 percent against label claim.
- Substantiated beyond-use dates per product, formulation, container, and storage condition.
- Licensure verified in every state the pharmacy ships into.
- Inspection history on file, including any findings and the pharmacy's responses.
- Patient-specific dispensing. No office stock, no bulk, no resale.
What your prescriber needs to know.
Compounded medications are not FDA approved. They are not reviewed by the FDA for safety, effectiveness, or manufacturing quality before they are dispensed. Your prescriber is responsible for the clinical decision, for the prescriber and patient relationship, and for informed consent.
The "essentially a copy" rule
The FDA shortage that permitted broad compounding of semaglutide and tirzepatide has ended. Compounding a drug that is essentially a copy of a commercially available approved drug is restricted.
Where a compounded product would be essentially a copy, the prescriber must document, for that individual patient, both the change from the approved drug and why that change makes a significant difference for that patient. Price, convenience, and availability never qualify. That documentation is the prescriber's responsibility, it is recorded on the order, and the dispensing pharmacy relies on it.
Aayu OS may suspend any product immediately, without notice and without that being a breach, if a shortage status, an FDA policy, or an eligibility determination changes.
Aayu OS does not process orders or payment for controlled substances.
See it with your own formulary.
Tell us what you order today and we will show you what it looks like in the portal.
Tell us what you order.
Send your current medication list and rough monthly volume. You get real pricing back against what you actually order, not a brochure. Usually within one business day.
- No obligation and no contract to look at pricing.
- A person who knows the product, not a call centre.
- If we are not the right fit for you, we will say so.
Prefer email? support@aayuos.com
Prefer to talk? (312) 625-1889